CAPSULAR TENSION RING AND STABILEYES

Ring, Endocapsular

FDA Premarket Approval P030023 S004

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval to include the ringject, a disposable injector/delivery system designed for use with capsular tension rings (ctrs), addition of the injector into the same sterile packaging process as the ctr and modification of the packaging configuration to accommodate the combined injector and the preloaded ctr. The device, as modified, will be marketed under the trade name ringject, model 375 and model 376. Ctrs are indicated for the stabilization of weakened, broken, or missing zonules that are suspected or observed during cataract extraction using phacoemulsification and continuous curbilinear capsulorhexis techniques in adults.

DeviceCAPSULAR TENSION RING AND STABILEYES
Classification NameRing, Endocapsular
Generic NameRing, Endocapsular
ApplicantOPHTEC USA, INC.
Date Received2014-07-21
Decision Date2015-11-13
PMAP030023
SupplementS004
Product CodeMRJ
Advisory CommitteeOphthalmic
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address OPHTEC USA, INC. 6421 Congress Ave., Suite 112 boca Raton, FL 33487

Supplemental Filings

Supplement NumberDateSupplement Type
P030023Original Filing
S008 2022-02-08 30-day Notice
S007 2018-12-18 30-day Notice
S006
S005 2016-06-10 30-day Notice
S004 2014-07-21 Normal 180 Day Track
S003
S002 2012-01-05 135 Review Track For 30-day Notice
S001 2011-10-19 Normal 180 Day Track No User Fee

NIH GUDID Devices

Device IDPMASupp
08717819070286 P030023 004
08717819070279 P030023 004

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.